Many cancer patients have benefited from targeted therapies that switch off cancer-driving oncogenes, but others, whose disease is driven by the loss of tumor-suppressing genes.
Gilead is paying $50 million upfront to enter into an immuno-oncology collaboration with Tango Therapeutics. The agreement gives Gilead the option to pick up the worldwide rights to five targets...